- Europa Press | December 05, 2018
The biotechnology company Derma Innovate has opened a round of funding in the crowdfunding platform ‘Capital Cell’, which aims to raise 400,000 euros to be able to validate their clinical trials on skin and hair regeneration in humans. The valuation of the company is of 5.1 million euros and the first lines of development will be on the market between 2019 and 2021.
“The therapies that exist today are palliative, but not always curative. In addition, the recovery process is complicated, very expensive and the results are not satisfactory”, justify from the company, that in collaboration with the Institute Ramón y Cajal for Health Research (IRYCIS), the Autonomous University of Madrid (UAM) and the Spanish National Research Council (CSIC), have developed an innovative technology that promotes cutaneous and capillary regeneration.
Its progress focuses on the local and transient production of reactive oxygen species that activate the proliferation of skin stem cells. By stimulating cutaneous regeneration, rapid and definitive results are obtained that did not exist until now and the success in capillary implants is also potentiated, with which it would be possible to intervene in the hair loss of different pathologies.
“Until today, our technology has been validated in mouse models, where we are able to reactivate skin regeneration by accelerating wound closure and also activating hair growth, and in human volunteer patients we have also been able to accelerate healing of extensive and chronic wounds. The next step is to validate clinical trials in humans, “says the Scientific Director of Derma Innovate, Jesus Espada.